Abstract 1733P
Background
On 24th of February 2022 reality in Ukraine changed. Ukraine became a victim of unfair attack of the neighbouring county. It influenced civilian population hugely, including the most vulnerable - children, elderly and patients. Since then, cancer patients became fighters of two fights - malignant disease and external aggressor. After more than a year of this reality Ukrainian oncologists would like to remind international society that the problem is not solved, and Ukrainians desperately need support.
Methods
It is generalized description of situation in the sphere of oncology in Ukraine since 24th of February 2022.
Results
According to Ukraine's Minister of Health, Victor Lyashko, during the first year of the war in Ukraine 1218 hospitals were damaged, 540 - partially destroyed and 173 destroyed completely. Among them - oncological hospitals. More than a million (∼1.2) Ukrainians currently stay on temporary occupied territories of the country and do not have access to qualified medical care. Around 7 million people had to move to safer areas of the country to stay safe and thousands of cancer patients had to move abroad for further treatment. It influenced the oncological landscape significantly. Oncological centers currently have to deal with 70% more patients than before the war. Moreover, the quantity of advanced stage disease has risen dramatically because a lot of people just couldn’t get medical help in time. Therefore, it caused bigger pressure on the medical system, requiring even more resources when they are so limited. At the same time, all clinical trials were put on pause leaving patients with advanced and rare diseases with no options for further treatment. Luckily, international society is extremely friendly to Ukraine providing Ukrainians with shelters and supplies, both material and intellectual. It helped and is helping a lot. But unfortunately, war is not over, and help is still needed.
Conclusions
The aim of the work is to show how things were going during this year of war and how they are actually going now for word to realize that even during the hardest time there is a place for high quality medical care. That only became possible thanks to huge support of international society, but there is still a lot to do to rebuild and improve reality that was destroyed on 24th of February.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23